Demand for Antibodies from 2022 to 2032 Is Projected To Expand At a Stellar CAGR Of 11.9%

The market for antibodies worldwide is expected to reach US$ 197.3 billion in value by 2022 and expand at a remarkable CAGR of 11.9% over the following ten years. By the end of 2032, the market is projected to have grown by a factor of three and achieve a valuation of US$ 608 billion.

Antibodies market growth potential in North America is anticipated to be driven by substantial spending in healthcare research and development. By the end of 2032, this regional market is anticipated to hold close to 49% of the global market share.

 

To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=194

 

The prevalence of chronic diseases has significantly increased over the world, and the regular outbreaks of viral illnesses have raised attention on healthcare. Government investment on research and the creation of new medicines has increased as a result of the increased focus on healthcare, which is anticipated to favour the market potential for antibodies throughout the course of the projected period.

It is anticipated that during the coming years, demand for antibodies would rise due to the high prevalence of uncommon diseases and the growing usage of monoclonal and polyclonal antibodies in their treatment and diagnosis. Through 2032, it is projected that the demand for research into bespoke antibodies will increase due to the rising popularity of customised medicine.

 

Key Segments in Antibodies Industry Research

  • By Product Type :
    • Monoclonal Antibodies
    • Polyclonal Antibodies
    • Immune Checkpoint Antibodies
    • Epitope Tag Antibodies
    • Isotype Control Antibodies
    • Primary Antibodies
    • Assay Antibodies
    • Others

 

  • By Application :
    • Drug Discovery & Development
    • Basic Research
    • Toxicity Screening
    • Biopharmaceutical Production
    • Drug Screening
    • Tissue Engineering
    • Forensic Testing
    • Others

 

  • By End User :
    • Biopharmaceutical Companies
    • Contract Research Organizations (CROs)
    • Academic & Research Institutes
    • Forensic Science Laboratories
    • Food & Beverage Companies
    • Diagnostic Centers
    • Others

 

Request more information about Report Methodology – https://www.factmr.com/connectus/sample?flag=S&rep_id=194

 

Competitive Landscape

Top companies in the antibodies market are focusing on advancing their research and fast-tracking the development of new antibodies to launch new products and gain a competitive advantage over other market players.

  • On September 19, 2022, Sandoz, a leader in biosimilars and generic pharmaceuticals, announced the progress of its biosimilar pipeline. This included positive results for the proposed biosimilar denosumab from ROSALIA Phase I/III clinical trial study. Denosumab is a human monoclonal antibody designed to bind and inhibit RANKL to reduce bone loss.

Key Companies

  • Novartis AG
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Sanofi SA
  • Eli Lilly and Co.

 

For in-depth competitive analysis, Buy Now – https://www.factmr.com/checkout/194

 

The global antibodies market, based on end user, is segmented into biopharmaceutical companies, contract research organizations (CROs), academic & research institutes, forensic science laboratories, food & beverage companies, diagnostic centers, and others.

Increasing demand for new drugs and pharmaceuticals owing to the high prevalence of chronic diseases across the world is projected to drive demand for antibodies in biopharmaceutical companies across the forecast period. Increasing investments in drug development and manufacturing are projected to favor antibody demand in biopharmaceutical companies and account for a dominant market share in the antibodies marketplace.

 

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

 

Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Leave a Reply

Your email address will not be published. Required fields are marked *